Welcome to LookChem.com Sign In|Join Free

CAS

  • or

222530-33-8

222530-33-8

Post Buying Request

222530-33-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

222530-33-8 Usage

Chemical Properties

White to off-white powder

Check Digit Verification of cas no

The CAS Registry Mumber 222530-33-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,2,5,3 and 0 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 222530-33:
(8*2)+(7*2)+(6*2)+(5*5)+(4*3)+(3*0)+(2*3)+(1*3)=88
88 % 10 = 8
So 222530-33-8 is a valid CAS Registry Number.
InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(16)13-9-6-4-5-8(7-9)10(14)15/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)

222530-33-8 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail

  • Alfa Aesar

  • (H62281)  cis-3-(Boc-amino)cyclohexanecarboxylic acid, 97%   

  • 222530-33-8

  • 250mg

  • 294.0CNY

  • Detail

  • Alfa Aesar

  • (H62281)  cis-3-(Boc-amino)cyclohexanecarboxylic acid, 97%   

  • 222530-33-8

  • 1g

  • 882.0CNY

  • Detail

  • Aldrich

  • (80393)  cis-3-(Boc-amino)cyclohexanecarboxylicacid  ≥98.0% (TLC)

  • 222530-33-8

  • 80393-500MG-F

  • 1,794.78CNY

  • Detail

222530-33-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name BOC-(+/-)-CIS-3-AMINOCYCLOHEXANE-1-CARBOXYLIC ACID

1.2 Other means of identification

Product number -
Other names cis-3-(Boc-amino)cyclohexanecarboxylic Acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:222530-33-8 SDS

222530-33-8Relevant articles and documents

Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof

-

Paragraph 0206-0211, (2021/07/24)

The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human

Chen, Jiehao,Efanov, Alexander M.,Fang, Xiankang,Jiang, Yi,Jun Zhang, Xue,Li, Lei,Lin, Hua V.,Liu, Jia,Liu, Lian Zhu,Long Hu, Zhi,Ma, Tianwei,Thomas, Melissa K,Wang, Fan,Wang, Jingru,Xiao, Fei,Xu, Jianfeng,Zeng, Mi,Zhang, Lei,Zhen Zhang, Hai,Zhou, Jingye,Zou, Haixia,Zou, Zack

supporting information, (2020/01/28)

The discovery and optimization of a novel series of GPR142 agonists are described. These led to the identification of compound 21 (LY3325656), which demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. Compound 21 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.

ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS

-

Paragraph 0583, (2017/03/21)

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 222530-33-8